Human Oncology Project
I am pleased to announce that our human Clinical Phase I/II trial is progressing well. Patients have
now been recruited and treated in the primary study as well as the extension study. As previously
stated, an interim analysis of this trial has been planned for July after which we will be in a position
to release results. An abstract describing our clinical trial was submitted and accepted by the
American Society of Clinical Oncology (ASCO) conference to be held late May in the USA. This is a
highly prestigious conference and will be an excellent forum for our introduction of EBC‐46 to the
broader oncology community.
